

Other new agents

Several novel chemotherapeutic agents developed in Japan, such as irinotecan, exatecan, UCN-01, NK911, capecitabine and S-1, have been evaluated in clinical trials for pancreatic cancer in Japan and/or other countries. It is hoped that improved therapeutic results might be obtained using these agents either singly or in combination with gemcitabine. This section focuses on irinotecan and NK911, clinical trials of which are ongoing for pancreatic cancer patients in Japan.

Irinotecan, a semisynthetic, water-soluble derivative of the plant alkaloid camptothecin, induces antitumor activity by inhibition of topoisomerase I. The single-agent antitumor activity of irinotecan in pancreatic cancer has been demonstrated in two phase II studies [24, 33]. In the first study conducted in Japan, administration of irinotecan at 100 mg/m² weekly or 150 mg/m² every other week to previously untreated patients resulted in a response rate of 11% in the 35 assessable patients treated [24]. In the second study, conducted by the European Organization for Research and Treatment of Cancer (EORTC), an irinotecan regimen of 350 mg/m² every 3 weeks induced partial responses in 9% of the 32 assessable patients [33]. A confirmatory phase II study is now underway in Japan. While no significant survival improvement with the combination of irinotecan and gemcitabine over gemcitabine alone has been reported recently [23], this agent may have the potential to be used in gemcitabine-refractory patients.

A new agent, developed based on the pathobiology of pancreatic cancer, is also being studied in a clinical trial for treatment of this disease. NK911 is a doxorubicin-encapsulated polymeric micellar nanoparticle [10]. The polymeric micelle carrier of NK911 consists of a block copolymer of polyethyleneglycol and polyaspartic acid. Polyethyleneglycol is expected to be in the outer shell of the micelle. NK911 has a highly hydrophobic inner core, and therefore can entrap a sufficient amount of doxorubicin. After the NK911 is extravasated from the tumor vessels, doxorubicin is released from NK911. It is suggested that pegylated liposomal doxorubicin (known as Doxil) can deliver doxorubicin to a solid tumor, via the enhanced permeability and retention (EPR) effect, more efficiently than NK911. This is because pegylated liposomal doxorubicin is more stable in the bloodstream. However, it is expected that NK911 can distribute more doxorubicin into cancer cells distant from the tumor vessel than can pegylated liposomal doxorubicin, once NK911 is extravasated from the tumor vessel. It is, therefore, suggested that NK911 may be more effective against cancers where the tumor vessel network is rough due to an abundant collagen-rich matrix, e.g. pancreatic cancer. In a phase I trial, NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. A partial response was obtained in one patient with gemcitabine

refractory pancreatic cancer [13]. A phase II study of NK911 is ongoing in Japan.

A novel arterial infusion chemotherapy

Homma and coworkers have reported a novel arterial infusion chemotherapy for advanced pancreatic cancer [8]. To restrict the blood flow into the pancreas, the peripancreatic blood vessels were embolized superselectively with microcoils. The catheter tip for continuous arterial infusion of 5-FU and cisplatin is placed in the splenic artery just proximal to the branching of the great pancreatic artery for treatment of the primary tumor, and in the common hepatic artery for treatment of metastatic liver lesions. In 31 patients with advanced pancreatic cancer, 2 achieved a complete response and 16 showed a partial response. The median survival period of all patients was 18.3 months. They concluded that this treatment is effective against both primary tumor and metastatic lesions in unresectable pancreatic cancer patients.

Other approaches in Japan

Allogeneic stem-cell transplantation has been proven to have potent antitumor effects not only in patients with hematologic malignancies but also in those with solid tumors [6, 32]. Successful nonmyeloablative allogeneic peripheral blood stem-cell transplantation has been reported in patients with metastatic renal cell carcinoma, and the results with this treatment are consistent with a graft-versus-tumor effect [4, 5]. Omuro and colleagues described a patient who showed continuous regression of unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral blood stem-cell transplantation, which was considered to be attributed to a graft-versus-tumor effect [21]. Based on the results of the report and those for other malignancies, clinical trials of nonmyeloablative allogeneic peripheral blood stem-cell transplantation are being conducted with pancreatic cancer patients in several institutes in Japan.

Increased understanding of the biology of pancreatic cancer could provide the potential to develop entirely novel treatment options. One innovative approach for therapy is a combination of interferon α and antisense K-ras [14]. We have shown that interferon α gene transduction into pancreatic cancer cells induces growth suppression and cell death in the cells; an effect that appears to be more prominent when compared with other types of cancers and normal cells. Another strategy developing for pancreatic cancer targets its characteristic genetic aberration, K-ras point mutation. It has been reported that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells [1, 2]. When these two gene therapy strategies are combined, the expression of antisense K-ras

RNA significantly enhances interferon α -induced cell death (1.3- to 3.5-fold), and suppresses subcutaneous growth of pancreatic cancer cells in mice. Because the 2',5'-oligoadenylate synthetase/RNaseL pathway, which is regulated by interferon and induces apoptosis of cells, is activated by double-strand RNA, it is plausible that the double-strand RNA formed by antisense and endogenous K-ras RNA enhances the antitumor activity of interferon α . This study suggested that the combination of interferon α and antisense K-ras RNA is a promising gene therapy strategy against pancreatic cancer.

Conclusion

Pancreatic cancer is a major cause of cancer-related mortality in Japan. At present, nonsurgical therapy is of limited value in the treatment of pancreatic cancer, but various approaches are being attempted that we hope will result in improved patient survival. The evolving understanding of molecular and genetic biology should facilitate research to develop novel target-based agents and to establish individualized therapy regimens for this disease.

References

- Aoki K, Yoshida T, Sugimura T, Terada M (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. *Cancer Res* 55:3810
- Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. *Mol Carcinog* 20:251
- Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 15:2403
- Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J (1999) Successful treatment of metastatic renal cell carcinoma with nonmyeloablative allogeneic peripheral-blood progenitor-cell transplantation: evidence for a graft-versus-tumor effect. *J Clin Oncol* 17:2044
- Childs R, Chernoff A, Contentin N, Bahceci E, Schrupp D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ, Clave E, Epperson D, Mayo V (2000) Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med* 343:750
- Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. *Blood* 88:1501
- Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y, Niitani H (2001) Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. *Int J Clin Oncol* 6:236
- Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y (2000) A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. *Cancer* 89:303
- Ikeda M, Okada S, Ueno H, Okusaka T, Tanaka N, Kuriyama H, Yoshimori M (2000) A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. *Hepatogastroenterology* 47:862
- Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y (1993) Block copolymer micelles as vehicles for drug delivery. *J Control Release* 24:119
- Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. *Br J Cancer* 85:939
- Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. *Oncology* 58:191
- Matsumura Y (2003) Phase I clinical trial of NK911, polymer micelle encapsulated doxorubicin. Proceedings of the Winter Symposium and 11th International Symposium on Recent Advances in Drug Delivery Systems; Salt-lake City, UT, 3-6 March 2003. Abstract 55
- Miura Y, Suzuki K, Hatanaka K, Yoshida K, Ohnami S, Kitade Y, Yoshida T, Aoki K (2003) Synergistic cytotoxic effect of antisense K-ras RNA and interferon alpha against pancreatic cancer cells. *Mol Ther [Suppl]* 7:S417
- Nose H, Okada S, Okusaka T, Furuse J, Yoshino M, Ogoshi K, Kato T, Miyaji M, Hoshino M, Ariyama J, Suyama M, Karasawa E, Yoshimori M (1999) 5-Fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study. *Hepatogastroenterology* 46:3244
- Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T, for the S-1 Cooperative Colorectal Carcinoma Study Group (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. *Br J Cancer* 83:141
- Okada S (1999) Non surgical treatments of pancreatic cancer. *Int J Clin Oncol* 4:257
- Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y (2001) Phase I trial of gemcitabine in patients with advanced pancreatic cancer. *Jpn J Clin Oncol* 31:7
- Okada S, Okusaka T, Ueno H, Ikeda M, Kuriyama H, Saisho T, Morizane C (2002) A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (abstract 682). *Proc Am Soc Clin Oncol* 21
- Okusaka T, Okada S, Ishii H, Nose H, Nakasuka H, Nakayama H, Nagahama H (1996) Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. *Jpn J Clin Oncol* 26:215
- Omuro Y, Matsumoto G, Sasaki T, Tanaka Y, Maeda Y, Sakamaki H, Hiruma K, Tsuruta K, Takahashi T (2003) Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *Bone Marrow Transplant* 31:943
- Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. *Cancer Chemother Pharmacol* 22:333
- Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar LA, Morganti A, Gruia G, Miller L, Green MR (2003) A randomized phase 3 study comparing efficacy and safety of gemcitabine and irinotecan to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy (abstract 1005). *Proc Am Soc Clin Oncol* 22:251

24. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A, Taguchi T (1994) A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer (in Japanese). *Gan To Kagaku Ryoho* 21:1039
25. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* 34:1715
26. Statistics and Information Department, Minister's Secretariat (2002) Vital statistics of Japan 2001 (in Japanese). Ministry of Health, Labor and Welfare, Tokyo
27. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. *Oncology* 57:202
28. Taguchi T, Furuse K, Fukuoka M, Shimoyama T, Morimoto K, Nakamura T, Furue H, Majima H, Niitani H, Ohta K, Wakui A, Nakao I, Tsukagoshi S (1996) LY188011 phase I study. Research Group of Gemcitabine (LY188011) (in Japanese). *Gan To Kagaku Ryoho* 23:1011
29. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, Amano H, Wada K (1998) Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. *Hepatogastroenterology* 45:2020
30. Tsuji A, Morita S, Horimi T, Takamats M, Takahashi I, Shirasaka T (2002) A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced pancreatic cancer (abstract 628). *Proc Am Soc Clin Oncol* 21
31. Ueno H, Okada S, Okusaka T, Ikeda M, Kuriyama H (2002) Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. *Oncology* 62:223
32. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE (1998) Allogeneic peripheral-blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. *J Clin Oncol* 16:986
33. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. *Ann Oncol* 6:129

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

T Okusaka^{*1}, Y Ito², H Ueno¹, M Ikeda¹, Y Takezako¹, C Morizane¹, Y Kagami² and H Ikeda²

¹Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; ²Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan

Gemcitabine has been reported to be a potent radiosensitiser in human pancreatic cell lines. This study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. In all, 42 patients with pancreatic cancer that was unresectable but confined to the pancreatic region were treated with external-beam radiation (50.4 Gy in 28 fractions over 5.5 weeks) and weekly gemcitabine (250 mg m⁻², 30-min infusion). Maintenance gemcitabine (1000 mg m⁻² weekly × 3 every 4 weeks) was initiated 1 month after the completion of the chemoradiotherapy and continued until disease progression or unacceptable toxicity. Of the 42 patients, 38 (90%) completed the scheduled course of chemoradiotherapy. The major toxicity was leucopenia and anorexia. There was one death attributed to duodenal bleeding and sepsis. The median survival time was 9.5 months and the 1-year survival rate was 28%. The median progression-free survival time was 4.4 months. In 35 patients with documented disease progression at the time of analysis, 34 (97%) showed distant metastasis as the cause of the initial disease progression. The chemoradiotherapy used in this study has a moderate activity against locally advanced pancreatic cancer and an acceptable toxicity profile. Future investigations for treatment with more systemic effects are warranted.

British Journal of Cancer (2004) 91, 673–677. doi:10.1038/sj.bjc.6602001 www.bjcancer.com

Published online 29 June 2004

© 2004 Cancer Research UK

Keywords: pancreatic cancer; chemoradiotherapy; gemcitabine; radiosensitiser

Pancreatic cancer is the fourth leading cause of cancer death in the United States and the fifth leading cause in Japan. The statistics indicate a rapid increase in the number of deaths and the death rate due to pancreatic cancer in Japan, but the precise reasons are not clear, except for smoking. Pancreatic cancer in most patients is surgically unresectable at the time of diagnosis because of the difficulty of early detection of this disease. For patients with locally advanced pancreatic cancer, chemoradiotherapy has been accepted as standard treatment because the results of previous randomised trials have indicated that concurrent external-beam radiation therapy and 5-fluorouracil (5-FU) therapy results in a significantly longer survival time than radiotherapy (Moertel *et al*, 1969; Gastrointestinal Tumor Study Group, 1981) or chemotherapy alone (Gastrointestinal Tumor Study Group, 1988). In attempts to improve the efficacy of the treatment, numerous trials using modified approaches of chemoradiotherapy have been conducted (Chakravarthy and Abrams, 1997; Okada, 1999). However, there has not yet been a regimen that has demonstrated superiority over conventional chemoradiotherapy performed in randomised controlled trials.

Gemcitabine is a novel deoxycytidine analog, which has demonstrated significant clinical benefit and survival improvement compared with 5-FU in patients with advanced pancreatic cancer (Burris *et al*, 1997). Gemcitabine has also been shown to be

a potent radiosensitiser in human pancreatic and other solid tumour cell lines (Lawrence *et al*, 1996; Shewach and Lawrence, 1996; van Putten *et al*, 2001), suggesting that the combination of radiotherapy and gemcitabine may improve survival in patients with locally advanced disease. A phase I trial that was conducted in our hospital determined the recommended dose of weekly gemcitabine for the phase II chemoradiotherapy trial to be 250 mg m⁻² (Ikeda *et al*, 2002). We report our results of the phase II study that was conducted to clarify the efficacy and toxicity of concomitant chemoradiotherapy with gemcitabine in patients with locally advanced pancreatic cancer.

PATIENTS AND METHODS

Patients eligible for this study had locally advanced pancreatic cancer for which they had not received any anticancer treatment. Each patient was required to meet the following eligibility criteria: pathological proof of adenocarcinoma of the pancreas; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; adequate bone marrow reserve (white blood cell count ≥4000 mm³, platelet count ≥100 000 mm³, haemoglobin level ≥10 g dl⁻¹); adequate renal function (normal serum creatinine and blood urea nitrogen levels, and a creatinine clearance level ≥60 mg min⁻¹); a serum aspartate aminotransferase (AST) level <2.5 times upper normal limit (UNL); a serum alanine aminotransferase (ALT) level <2.5 times UNL; and written informed consent. Patients with obstructive jaundice were

*Correspondence: Dr T Okusaka; E-mail: tokusaka@ncc.go.jp

Received 29 March 2004; accepted 24 May 2004; published online 29 June 2004

required to have a serum total bilirubin level of less than 2.0 mg dl^{-1} after biliary drainage. Pretreatment staging included ultrasonography and dynamic computed tomography (CT) scans of both the abdomen and the chest. The possibility for resection of the local tumour was assessed by dynamic CT and/or angiography. Obstruction or bilateral invasion of the portal vein and/or tumour encasement of the celiac or superior mesenteric arteries was considered to be unresectable. Patients were excluded if they met the following criteria: concomitant malignancy, pleural and/or peritoneal effusion, active ulcer of the gastrointestinal tract, active infection, severe heart disease, pregnant or lactating females, or other serious medical conditions. The goal was set at 40 eligible patients. This number of patients was planned using a design based on the assumptions that the median survival time in conventional chemoradiotherapy was 10 months, expected median survival time was 14 months, type I error was 5% (one-tailed) and statistical power was 70%.

Radiotherapy was delivered via a racetrack microtron (MM50, Scanditronix, Upsala, Sweden) with a 25 MV X-rays. A total dose of 50.4 Gy was delivered in 28 fractions over 5.5 weeks. All patients had treatment planning, CT scans (X-vision, Toshiba, Tokyo) and FOCUS (version 3.2.1, CMS, St Louis, MO, USA) was used as a radiotherapy treatment planning system. Clinical target volume (CTV) included the primary tumour, nodal involvement detected by CT scan and regional draining and paraaortic lymph nodes, which included the peripancreatic nodes, celiac and superior mesenteric axes. Planning target volume was defined as CTV plus a 10-mm margin. Four field techniques (anterior, posterior and opposed lateral fields) were used. Spinal cord dose was maintained below 45 Gy and $\geq 50\%$ of liver was limited to $\leq 30 \text{ Gy}$, $\geq 50\%$ of both kidneys were limited to $\leq 20 \text{ Gy}$.

Gemcitabine at a dose of 250 mg m^{-2} was given intravenously over 30 min starting 2 h before radiotherapy weekly for 6 weeks. This schedule was based on an *in vitro* study which revealed that gemcitabine induced its radiosensitising effect in cells within 2 h (Lawrence *et al*, 1997). Toxicity was assessed according to the National Cancer Institute - Common Toxicity Criteria version 2.0. When grade 3 haematological toxicity, serum creatinine of 1.5–2.0 times UNL, total bilirubin level of 3.0–5.0 times UNL, serum AST/APT of 5.0–10 times UNL and/or grade 2 nonhaematological toxicity (excluding nausea, vomiting, anorexia, fatigue, constipation, alopecia and dehydration) were observed, gemcitabine administration was omitted and postponed to the next scheduled treatment day. The radiotherapy was also suspended, and then resumed when the toxicities recovered. In patients who experienced the above adverse effects, dose reduction of gemcitabine to 200 mg m^{-2} was allowed in subsequent administrations. The combined treatment was discontinued when grade 3 leucopenia and/or neutropenia with high fever, grade 4 haematological toxicities after dose reduction of gemcitabine, serum creatinine of > 2.0 times UNL, total bilirubin level of > 5.0 times UNL, serum AST/APT of > 10 times UNL, grade 3 or 4 nonhaematological toxicities (excluding nausea, vomiting, anorexia, fatigue, constipation, alopecia and dehydration), grade 4 vomiting, a total of 2 weeks of delay due to toxicity for any reason or tumour progression were observed. At 1 month after the completion of chemoradiotherapy, maintenance chemotherapy of gemcitabine at a dose of 1000 mg m^{-2} was administered as a 30-min intravenous infusion weekly for 3 weeks with 1-week rest until disease progression or unacceptable toxicity. Follow-up CT was performed within 1 week after the completion of chemoradiotherapy, and thereafter every 2 months to evaluate tumour response according to the WHO criteria (World Health Organization, 1979).

Progression-free and overall survival times were calculated from the first day of treatment using the Kaplan–Meier method (Kaplan and Meier, 1958). Serum CA 19-9 levels were measured monthly by a radioimmunoassay using the Centocor radioimmunoassay kit (Centocor, Inc., Malvern, PA, USA).

RESULTS

Patients and treatments

In all, 42 patients were enrolled in the study between July 2001 and July 2002. Patient characteristics are listed in Table 1. A total of 38 patients (90%) received the full regimen of chemoradiotherapy, and the remaining four patients (10%) discontinued the treatment after 18.0–45.0 Gy. The reasons for the treatment discontinuation were elevated serum ALT of > 10 times UNL (two patients), duodenal bleeding (one), and patient's refusal of treatment due to general fatigue (one). After discontinuation of the chemoradiotherapy, the two patients who showed the ALT elevation suspected as gemcitabine-related toxicity received chemoradiotherapy using 5-FU, and the other two patients underwent only supportive care. Of 241, 30 (12%) planned gemcitabine injections (0.7 injections per patient) were omitted owing to adverse events including grade 3 or more leucopenia and/or neutropenia, grade 2 fever, grade 2 skin rash and patient's refusal due to nausea, vomiting or fatigue. In three patients who showed grade 4 leucopenia and/or neutropenia, the dose of gemcitabine was modified in subsequent injections. Maintenance chemotherapy was initiated in 23 of the 38 patients who completed the full regimen of chemoradiotherapy. Of the remaining 15 patients, seven showed deterioration of general condition due to disease progression before initiating the chemotherapy, seven refused the treatment due to appetite loss (4) or general fatigue (3) and one transferred to another hospital (1).

Response and survival

Tumour response was determined in 40 patients. Two patients were excluded from the protocol efficacy analysis because their treatment was switched over to chemoradiotherapy using 5-FU before the response evaluation due to the ALT elevation. Nine patients (21%) achieved a partial response, 26 (62%) remained stable and five (12%) showed progressive disease demonstrated by the development of distant metastases. No patients could undergo tumour resection even after the completion of chemoradiotherapy because of infiltration of the adjacent large vessels. In 22 (76%) of the 29 patients with a pretreatment serum CA19-9 (carbohydrate antigen 19-9) level of 100 U ml^{-1} or greater, the level was reduced more than 50% within 14 weeks after initiation of treatment.

Table 1 Patient characteristics

Number of patients	42
Gender	
Male	19 (45%)
Female	23 (55%)
Age (years)	
Median (range)	59 (43–73)
ECOG performance status	
0	12 (29%)
1	30 (71%)
Tumour location	
Head	21 (50%)
Body–tail	21 (50%)
CEA (ng ml^{-1})	
Median (range)	11 (1.0–62.7)
CA19-9 (U ml^{-1})	
Median (range)	2775 (1–15 620)

ECOG = Eastern Cooperative Oncology Group; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9.

A total of 35 patients documented disease progression at the time of analysis. The initial sites of disease progression are listed in Table 2. The pattern of failure was distant metastases in 33 patients (94%), local-regional recurrence in one patient (3%) and both in one patient (3%). The median progression-free interval and the median survival time were 4.4 and 9.5 months, respectively. The overall 1- and 2-year survival rates were 28 and 23%, respectively (Figure 1).

Toxicity

The acute toxicity is summarised in Table 3. The haematological toxicity was relatively brief and reversible in most patients. Grade 3-4 leucopenia and neutropenia occurred in 22 (52%) and 14 (33%) of the patients, respectively. Grade 3 thrombocytopenia occurred in one patient (2%) on the day after the chemoradiotherapy completion. The patient, who showed grade 4 anaemia, suffered catastrophic duodenal bleeding requiring embolisation under angiography. She exhibited cholangitis and sepsis subsequently and died on day 63.

The most common nonhaematological toxicity was anorexia, which was observed in 38 patients (90%). In total, 14 patients (33%) required intravenous hyperalimentation. In all, 33 patients (79%) complained of fatigue and one of them refused continuation of the chemoradiotherapy. Nine patients (21%) experienced grade 3 nausea. Liver function abnormality was another major adverse effect. Four patients (10%) showed grade 3 elevation of serum transaminase levels. Two of them discontinued the treatments after 19.8 and 21.6 Gy, respectively, due to serum ALT elevation of 10 times UNL according to the protocol criteria (maximum level: 452 and 435 IU l⁻¹), although the serum ALT levels of both recovered

Table 2 Patterns of initial disease progression

Local	No. (%)
Distant metastasis	33 (94)
Peritoneum	17 (49)
Liver	15 (43)
Lymph node	1 (3)
Ovary	1 (3)
Bone	1 (3)
Local and distant metastasis	1 (3)




Figure 1 Progression-free survival and overall survival curves of patients with locally advanced pancreatic cancer receiving radiotherapy with gemcitabine.

Table 3 Acute toxicity

Grade	1 (%)	2 (%)	3 (%)	4 (%)
Haematological toxicity				
Leucocytopenia	3 (7)	17 (40)	21 (50)	1 (2)
Neutropenia	9 (21)	15 (36)	11 (26)	3 (7)
Thrombocytopenia	22 (52)	2 (5)	1 (2)	0 (0)
Anaemia	21 (50)	17 (40)	0 (0)	1 ^a (2)
Nonhaematological toxicity				
Total bilirubin	10 (24)	5 (12)	1 (2)	0 (0)
AST	14 (33)	5 (12)	1 (2)	0 (0)
ALT	15 (36)	11 (26)	4 (10)	0 (0)
ALP	15 (36)	5 (12)	0 (0)	0 (0)
Creatinine	0 (0)	0 (0)	0 (0)	0 (0)
Anorexia	9 (21)	5 (12)	10 (24)	14 (33)
Nausea	11 (26)	11 (26)	9 (21)	0 (0)
Vomiting	10 (24)	7 (17)	0 (0)	0 (0)
Diarrhoea	1 (2)	1 (2)	0 (0)	0 (0)
Mucositis	0 (0)	0 (0)	0 (0)	0 (0)
Duodenal ulcer	0 (0)	0 (0)	0 (0)	1 ^a (2)
Fatigue	17 (40)	14 (33)	2 (5)	0 (0)
Skin rash	0 (0)	1 (2)	0 (0)	0 (0)
Infection	0 (0)	0 (0)	0 (0)	1 ^a (2)

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase. ^aOne patient died of duodenal bleeding and sepsis.

to the grade 1 levels 4 days after discontinuation of the treatment. We suspected that the ALT elevation in these two patients was gemcitabine-related toxicity because it was never reproduced after their treatment was switched over to chemoradiotherapy using 5-FU. One patient suffered unexpected acute abdominal pain requiring morphine 2 months after the completion of the chemoradiotherapy and was diagnosed with perforation of pancreatic pseudocyst into the duodenum. This pain disappeared completely by only medical management within 1 week. No patients experienced any symptoms considered to be late toxicity as of the time of analysis.

DISCUSSION

Based on previous randomised trials (Moertel *et al*, 1969; Gastrointestinal Tumor Study Group, 1981; Gastrointestinal Tumor Study Group, 1988), concurrent external-beam radiotherapy and 5-FU have been generally accepted as the standard treatment for locally advanced carcinomas. To intensify the treatment efficacy, various anticancer agents and radiation schedules are being investigated in clinical trials of chemoradiotherapy (Roldan *et al*, 1988; Seydel *et al*, 1990; Wagener *et al*, 1996; Thomas *et al*, 1997; Prott *et al*, 1997; Okusaka *et al*, 2001). However, marked improvement in their survival has not been observed. In an attempt to optimise radiosensitisation, radiotherapy with protracted 5-FU infusion has been examined recently, but the median survival times were similar to those observed in previous studies (Ishii *et al*, 1997).

Gemcitabine has been expected to be an agent that improves the outcome of chemoradiotherapy for locally advanced pancreatic cancer because it is a chemotherapeutic drug having meaningful palliative and prognostic impact against advanced pancreatic cancer, and it is also a potent radiosensitiser. Several experimental studies have shown that more than one mechanism leads to the potentiation of radiation-induced cell killing by gemcitabine (Lawrence *et al*, 1996; Shewach and Lawrence, 1996; van Putten *et al*, 2001). In clinics, various phase I studies for radiotherapy with gemcitabine have been conducted (McGinn *et al*, 2001; Pipas *et al*, 2001; Wolff *et al*, 2001; Ikeda *et al*, 2002; Poggi *et al*, 2002),

although the efficacy and safety of this combination have not been fully elucidated in phase II trials. A phase I trial that was conducted in our hospital determined the recommended dose of weekly gemcitabine in the phase II chemoradiotherapy trial to be 250 mg m⁻², because three of the six patients give a dose of 350 mg m⁻² of gemcitabine demonstrated dose-limiting toxicities involving neutropenia/leucopenia and elevated transaminase (Ikeda *et al*, 2002).

The toxicity associated with radiotherapy with gemcitabine was relatively severe in this phase II study. Grade 3–4 leucopenia and neutropenia were observed in 52 and 33% of the patients, respectively, although none of the patients showed neutropenic fever. Nausea and anorexia were the most serious non-haematological toxicities in this treatment; 73% of the patients experienced various degrees of nausea and 33% required intravenous hyperalimantation. In all, 78% of the patients complained of general fatigue and one patient (2%) refused continuation of the treatment because of this adverse effect. These troublesome toxicities observed in this study seem to be more frequent and more severe compared with those in 5-FU-based chemoradiotherapy (Ishii *et al*, 1997). There was one death attributed to duodenal bleeding, which was arrested by transcatheter arterial embolisation, but deterioration of the general condition and lethal sepsis were induced subsequently.

The present study, in which 42 patients with locally advanced pancreatic cancer were treated with radiotherapy and weekly gemcitabine, documented a marginal impact on patient survival; the median survival time of 9.5 months is comparable to that in patients receiving conventional chemotherapy using 5-FU. However, the incidence rate of distant metastasis at the time of disease progression was remarkably higher with this treatment (97%) as compared to that with 5-FU-based chemoradiotherapy, which was reported to be 50% in our previous study (Ishii *et al*, 1997). This suggests that gemcitabine at a dose of 250 mg m⁻² is a potent radiosensitiser for controlling local disease, but its ability as a chemotherapeutic agent is insufficient to counteract systemic tumour spread. To improve prognosis for these patients, future investigations for treatment with more systemic effects are warranted.

In an effort to increase capacity for systemic therapy, reduction of the radiation field has been attempted. Investigators at the University of Michigan elected to radiate the primary tumour alone, without the inclusion of regional lymph nodes, and administer full-dose gemcitabine concurrently, because the use of full-dose gemcitabine requires reduction of the radiation dose, based on their prior clinical experience (McGinn *et al*, 2001; Muler

et al, 2004). Reduction of the radiation field may be one of the strategies not only for intense systemic therapy but also for decreasing the troublesome gastrointestinal toxicity often observed in our study; our recent retrospective study showed that a larger planning target volume for irradiation was only a significant predictor of severe acute intestinal toxicity in patients treated with chemoradiotherapy using gemcitabine (Ito *et al*, 2003).

Crane *et al* (2002) retrospectively compared the toxicity and efficacy of concurrent gemcitabine-based chemoradiation with those of concurrent 5-FU-based chemoradiation in patients with unresectable pancreatic cancer treated in the University of Texas MD Anderson Cancer Center. In the study, there was a significantly higher severe toxicity rate in patients treated with gemcitabine than in those with 5-FU, although the median survival times were similar between the two arms (gemcitabine vs 5-FU: 11 vs 9 months). They concluded that concurrent gemcitabine and radiotherapy could be an extremely difficult combination to administer safely, with a very narrow therapeutic index. Recently, investigators in Taiwan reported favourable results for radiotherapy with concurrent gemcitabine administration (600 mg m⁻² week⁻¹ for 6 weeks) in a small randomised study (Li *et al*, 2003). The gemcitabine-based chemoradiotherapy showed a significantly better median survival time (14.5 months) and a comparable toxicity profile in comparison with the 5-FU-based chemoradiotherapy (7.1 months). However, the number of enrolled patients in this study was only 16–18 in each arm. The results need further confirmation by larger multi-institutional clinical trials.

In summary, the chemoradiotherapy used in this study has a moderate activity against locally advanced pancreatic cancer and an acceptable toxicity profile, but appears to have more frequent acute toxicities compared with conventional chemoradiotherapy using 5-FU. Most patients who underwent this therapy demonstrated rapid appearance of distant metastasis. To explore innovative approaches for locally advanced pancreatic cancer, future investigations for treatment with more systemic effects and less toxicity are needed.

ACKNOWLEDGEMENTS

This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan. We thank Ms K Kondo for her help with the manuscript preparation.

REFERENCES

- Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 15: 2403–2413
- Chakravarthy A, Abrams RA (1997) Radiation therapy and 5-fluorouracil in pancreatic cancer. *Semin Radiat Oncol* 7: 291–299
- Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? *Int J Radiat Oncol Biol Phys* 52: 1293–1302
- Gastrointestinal Tumor Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil. *Cancer* 48: 1705–1710
- Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. *J Natl Cancer Inst* 80: 751–755
- Ikeda M, Okada S, Tokuyue K, Ueno H, Okusaka T (2002) A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. *Br J Cancer* 20(86): 1551–1554
- Ishii H, Okada S, Tokuyue K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. *Cancer* 79: 1516–1520
- Ito Y, Okusaka T, Kagami Y, Ueno H, Ikeda M, Sumi M, Imai A, Ikeda H (2003) Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 57: S383–4

- Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 63: 457–481
- Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. *Int J Radiat Oncol Biol Phys* 34: 867–872
- Lawrence TS, Chang EY, Hahn TM, Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). *Clin Cancer Res* 3: 777–782
- Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. *Int J Radiat Oncol Biol Phys* 57: 98–104
- McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 19: 4202–4208
- Moertel CG, Childs Jr DS, Reitemeier RJ, Colby Jr MY, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. *Lancet* 2: 865–867
- Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM (2004) Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. *J Clin Oncol* 22: 238–243
- Okada S (1999) Non-surgical treatments of pancreatic cancer. *Int J Clin Oncol* 4: 257–266
- Okusaka T, Okada S, Tokuyue K, Wakasugi H, Saisho H, Ishikawa O, Matsuno S, Sato T, Sato K (2001) Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. *Cancer* 91: 1384–1389
- Pipas JM, Mitchell SE, Barth Jr RJ, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. *Int J Radiat Oncol Biol Phys* 50: 1317–1322
- Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL (2002) Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 54: 670–676
- Prott FJ, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O, Potter R, Sulkowski U, Rube C, Berns T, Willich N (1997) Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. *Br J Cancer* 75: 597–601
- Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. *Cancer* 61: 1110–1116
- Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR (1990) Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. *Cancer* 65: 1478–1482
- Shewach DS, Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. *Invest New Drugs* 14: 257–263
- Thomas Jr CR, Weiden PL, Traverso LW, Thompson T (1997) Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II Study of 16th Puget Sound Oncology Consortium (PSOC-703). *Am J Clin Oncol* 20: 161–165
- van Putten JW, Groen HJM, Smid K, Peters GJ, Kampinga HH (2001) End-joining deficiency and radiosensitization induced by gemcitabine. *Cancer Res* 61: 1585–1591
- Wagener DJ, Hoogenraad WJ, Rougier P, Lusinchi A, Taal BG, Veenhof CH, de Graeff A, Conroy T, Curran D, Sahnoud T, Wils J (1996) Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. *Eur J Cancer* 32A: 1310–1313
- Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. *Clin Cancer Res* 7: 2246–2253
- World Health Organization (1979) *WHO Handbook for Reporting Results of Cancer Treatment*, Offset Publication 48 Geneva: World Health Organization

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

Hideki Ueno^a Takuji Okusaka^a Masafumi Ikeda^a Koich Tokuyue^b

Divisions of ^aHepatobiliary and Pancreatic Oncology, and ^bRadiation Oncology, National Cancer Center Hospital, Tokyo, Japan

Key Words

Chemoradiotherapy · 5-Fluorouracil · Hyperfractionation · Pancreatic cancer · Phase I study · Radiation therapy

Abstract

Objective: This study investigated the maximum-tolerated dose of hyperfractionated radiation therapy with protracted 5-fluorouracil (5-FU) infusion in patients with locally advanced, unresectable pancreatic cancer. **Methods:** Five cohorts of patients were scheduled to receive escalating doses of hyperfractionated radiation therapy (range, 45.6–64.8 Gy). All patients received two fractions of 1.2 Gy each (separated by 6 h) per day for 5 days a week, and received protracted 5-FU infusion (200 mg/m²/day) during the radiation course. The maximum-tolerated dose was defined as one dose level below the dose at which more than one third of 3–6 patients experienced dose-limiting toxicity. **Results:** Twenty-nine patients were enrolled in this study. The most common toxicities were nausea/vomiting and anorexia. Although 1 patient developed bleeding from a gastric ulcer 3 months after the completion of chemoradiotherapy, the maximum-tolerated dose was not reached even at the highest dose

level (level 5, 64.8 Gy). The median survival time was 12.2 months and the 1-year survival rate was 55.0%. **Conclusion:** The toxicity associated with our regimen was tolerable up to dose level 5 (64.8 Gy). We are currently conducting a phase II study of this hyperfractionated radiation therapy with protracted 5-FU infusion at a dose of 64.8 Gy.

Copyright © 2004 S. Karger AG, Basel

Introduction

Because of the difficulty in diagnosing pancreatic cancer early, the vast majority of patients have unresectable disease at the time of diagnosis. About 30–50% of the unresectable cases have localized disease without distant metastases. In the treatment of locally advanced, unresectable pancreatic cancer, radiotherapy with concomitant chemotherapy has been the treatment of choice since it offers better survival rates when compared to treatment by radiotherapy or chemotherapy alone [1, 2]. However, improvement in chemoradiotherapy for pancreatic cancer is necessary because chemoradiotherapy has achieved only modest improvements in median survival and minimal increases in long-term survival [3].

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2004 S. Karger AG, Basel
0030-2414/04/0674-0215\$21.00/0

Accessible online at:
www.karger.com/ocl

Hideki Ueno, MD
Hepatobiliary and Pancreatic Oncology Division
National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku
Tokyo 104-0045 (Japan)
Tel. +81 3 3542 2511, Fax +81 3 3542 3815, E-Mail hiueno@ncc.go.jp

Hyperfractionation, the administration of a larger number of smaller doses per fraction, is one of the promising and tempting alternatives to conventional radiation therapy. One possible advantage of hyperfractionation is that this approach may permit an improvement in tumor control by increasing the total tumor dose without increasing the risk of late complications [4]. Several encouraging results of this therapeutic modality have been reported in patients with head and neck cancer or lung cancer [5, 6]. However, only limited information about hyperfractionated radiation therapy is available for pancreatic cancer. Therefore, we conducted a phase I study of hyperfractionated radiation therapy with 5-fluorouracil (5-FU) in patients with locally advanced pancreatic cancer. In the present study, 5-FU was administered by protracted infusion during the radiation course to intensify the anti-tumor effect of chemotherapy. The primary objective of this study was to assess the toxicity of hyperfractionated radiation therapy with protracted 5-FU infusion and to determine the maximum-tolerated dose of radiation in this combined treatment.

Patients and Methods

Patients

Eligibility criteria included (1) locally advanced unresectable pancreatic cancer; (2) histologically or cytologically confirmed adenocarcinoma of the pancreas; (3) 20–74 years of age; (4) an Eastern Cooperative Oncology Group performance status of 0–2, and (5) no prior anti-cancer treatment. Required pretreatment laboratory data included white blood cell count $\geq 4,000/\mu\text{l}$, hemoglobin level ≥ 10 g/dl, platelet count $\geq 100,000/\mu\text{l}$, normal serum creatinine level, serum total bilirubin level ≤ 2.0 mg/dl, serum albumin level ≥ 3.0 g/dl and serum transaminase level $\leq 2.5 \times$ upper normal limit. Exclusion criteria were: concomitant malignancy; pleural and/or peritoneal effusion; active ulcer of the gastrointestinal tract; active infection; severe heart disease; pregnant or lactating females, or other serious medical conditions. A chest X-ray and abdominal computed tomography (CT) were performed on all patients before treatment. The disease was considered locally advanced if abdominal CT revealed celiac trunk and/or superior mesenteric artery encasements with no evidence of systemic metastasis. Diagnostic laparoscopy was not performed. Histological and/or cytological confirmation was obtained by needle biopsy. Endoscopic or percutaneous biliary drainage was performed before treatment in patients with obstructive jaundice. This protocol was approved by the Institutional Review Board of the National Cancer Center. All patients received a full explanation of this study and gave written informed consent before entry into the study.

Treatment

The study design consisted of a sequential dose escalation of radiation therapy. The radiation dose level was planned in five cohorts as shown in table 1. The starting dose of radiation was

Table 1. Dose-escalation scheme for maximum-tolerated doses in hyperfractionated radiation therapy

Study cohort	Dose/fraction Gy	Total fractions	Total dose, Gy	Treatment duration, days
1	1.2	38	45.6	25
2	1.2	42	50.4	29
3	1.2	46	55.2	31
4	1.2	50	60.0	33
5	1.2	54	64.8	37

Treatment duration is given from the first day to the last day of radiation.

45.6 Gy, deemed safe based on the results of previous studies of hyperfractionation for pancreatic cancer [7–9]. Dose escalations at 4.8-Gy increments were planned if the previous dose had been tolerated. All patients received two fractions of 1.2 Gy each (separated by 6 h) per day for 5 days a week using 10–14 MV X-rays from a microtron (MM22, Scanditronix, Uppsala, Sweden). Treatment planning was determined by a three-dimensional treatment planner (FOCUS, Computerized Medical Systems, St. Louis, Mo., USA). Contours of the clinical target volume, which included the primary tumor, regional lymph nodes detected by CT, and para-aortic regions at celiac and supramesenteric axes were manually outlined on serial CT images displayed on a monitor. The definition of the regional lymph nodes followed the 6th edition of the UICC TNM Classification. Para-aortic lymph node metastasis was considered distant metastasis. A planning target volume which included a 10-mm margin of normal tissue surrounding the clinical target volume was defined on each CT image and on the craniocaudal dimension. Four field techniques (anterior, posterior and opposed lateral fields) were used. Spinal cord dose was maintained below 45 Gy, $\geq 50\%$ of liver was limited to ≤ 30 Gy, and $\geq 50\%$ of both kidneys were limited to ≤ 20 Gy. Chemotherapy consisted of protracted infusion of 5-FU at a dose of 200 mg/m²/day, which began on the first day of radiation and continued through the entire radiation course. One week after the completion of chemoradiotherapy, maintenance chemotherapy of 5-FU (500 mg/m², drip infusion) was given weekly until disease progression or unacceptable toxicity.

The toxicity of the treatment was scored according to the criteria of the Japan Society for Cancer Therapy [10], which are fundamentally similar to the National Cancer Institute common toxicity criteria. Both radiation therapy and chemotherapy were suspended for grade 3 hematological toxicity or grade 2 non-hematological toxicity excluding nausea/vomiting and anorexia during the treatment course, and treatment was restarted when toxicity was resolved. Dose-limiting toxicity (DLT) was defined as grade 3 or 4 non-hematological toxicities (excluding nausea/vomiting and anorexia) or grade 4 hematological toxicity occurring during chemoradiotherapy or within 4 weeks after completing treatment. If both radiation therapy and chemotherapy were suspended for more than 10 days due to adverse effects, the adverse effects were considered DLT.

Radiation dose escalation was scheduled to proceed as follows. Initially, 3 patients were to be studied in cohort 1. If none of the initial 3 patients in a cohort experienced DLT, the radiation dose was to be increased in the next 3 patients according to the schedules listed in table 1. If 1 or 2 of the initial 3 patients in a cohort experienced DLT, a maximum of 3 additional patients were entered into the cohort. If only 1 or 2 of 6 patients experienced DLT, dose escalation would continue. If 3 or more patients experienced DLT at a given dose level, then the previous dose level would be considered maximum-tolerated dose. Dose escalation to the next cohort was allowed after observing a previous cohort for a minimum of 4 weeks after the completion of chemoradiotherapy.

Follow-up CT was performed every 2 months to assess objective tumor response according to World Health Organization criteria [11]. Progression-free and overall survival were measured from the 1st day of study entry, and the survival rate was calculated by the Kaplan-Meier method. Serum CA 19-9 levels were measured monthly by radioimmunoassay using the Centocor radioimmunoassay kit (Centocor, Malvern, Pa., USA).

Results

Patient Characteristics

Between April 1999 and May 2001, 29 patients with locally advanced, unresectable pancreatic cancer were enrolled in the study at the National Cancer Center Hospital, Tokyo, Japan. The demographic characteristics of the 29 patients are listed in table 2. Relatively many patients with pancreatic body-tail cancer were enrolled in the study. All patients were in stage III according to the UICC TNM Classification (ed 6).

Toxicities

All 29 patients were assessable for toxicity. Two of the 29 patients failed to complete chemoradiotherapy for reasons other than toxicity: 1 patient at dose level 1 abandoned treatment after 25.2 Gy because of disease progression, and another patient at dose level 3 refused to continue treatment after 50.4 Gy, although there were no clinically significant adverse effects. Of the 27 patients evaluable for DLT, 22 (81%) completed the scheduled course of chemoradiotherapy. However, the remaining 5 had to abandon treatment because of adverse effects: nausea/vomiting and anorexia (3 patients), alanine aminotransferase elevation (1 patient) and thrombocytopenia (1 patient). Table 3 shows the toxicities that occurred during chemoradiotherapy or within 4 weeks after completing treatment. Hematological toxicity was relatively mild and reversible. Two patients exhibited grade 3 neutropenia, but these toxicities recovered immediately after interruption of chemoradiotherapy. Although thrombocytopenia was a rare toxicity, 1 patient at level 5 showed

Table 2. Patient characteristics (n = 29)

Characteristics	Patients	
	n	%
Gender		
Men	17	59
Women	12	41
Performance status		
0	5	17
1	24	83
Biliary drainage	7	24
Tumor location		
Head	9	31
Body-tail	20	69

Median carcinoembryonic antigen was 2.9 ng/ml (range: 0.9–42.1) and median CA 19-9 429 U/ml (range: 1–16,680). Median age of the patients was 59 years (range 32–74).

grade 4 thrombocytopenia after 52.8 Gy. Since this thrombocytopenia persisted after discontinuation of chemoradiotherapy, bone marrow aspiration was performed, and the patient was diagnosed with myelodysplastic syndrome. The most common non-hematological toxicities were nausea/vomiting and anorexia, which were observed in 27 (93%) and 24 patients (83%), respectively. These adverse effects were generally mild to moderate, but 5 patients required temporary treatment interruption (median, 2 days; range, 2–5 days) and 3 patients abandoned chemoradiotherapy because of prolonged toxicities. Other non-hematological toxicities included diarrhea and liver dysfunction, but these were also generally mild and transient. During the median follow-up period of 8.2 months (range, 1.7–26 months), late radiation-related toxicity was observed in only 1 patient, who developed bleeding from a gastric ulcer 3 months after the completion of chemoradiotherapy (level 1, 45.6 Gy) and then recovered from the ulcer by conservative treatment. There were no life-threatening toxicities, and no treatment-related deaths occurred. Table 4 summarizes the DLT observed in the current study. The maximum-tolerated dose of this phase I study was not reached even at the highest dose level (level 5, 64.8 Gy).

Therapeutic Results and Patient Outcome

Six patients (21%) achieved a partial response, 19 (66%) remained stable and 4 (14%) showed progressive disease demonstrated by the development of distant metastases. The serum CA 19-9 level was reduced more than

Table 3. Treatment-related toxicity (n = 29)

Toxicities	Study cohort														
	1 45.6 Gy (n = 6)			2 50.4 Gy (n = 3)			3 55.2 Gy (n = 7)			4 60.0 Gy (n = 6)			5 64.8 Gy (n = 7)		
	1, 2	3	4	1, 2	3	4	1, 2	3	4	1, 2	3	4	1, 2	3	4
<i>Hematological</i>															
Anemia	1	0	0	0	0	0	4	0	0	0	0	0	0	0	0
Leukocytopenia	3	0	0	3	0	0	6	1	0	3	0	0	4	0	0
Neutropenia	3	0	0	2	0	0	2	2	0	2	0	0	1	0	0
Thrombocytopenia	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1
<i>Non-hematological</i>															
Anorexia	2	3	0	2	0	0	4	3	0	1	3	0	3	3	0
Nausea/vomiting	5	0	0	3	0	0	7	0	0	3	2	0	7	0	0
Diarrhea	1	0	0	1	0	0	1	1	0	1	0	0	3	0	0
Stomatitis	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
AST/ALT	3	0	0	1	0	0	3	0	0	1	1	0	2	0	0
Alkaline phosphatase	1	0	0	0	0	0	1	0	0	2	0	0	0	0	0
Skin rash	1	0	0	0	0	0	2	0	0	1	0	0	0	0	0
Abdominal pain	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0
Fatigue	3	1	0	2	0	0	5	0	0	4	0	0	5	0	0
Weight loss	0	0	0	1	0	0	2	0	0	2	0	0	1	0	0

AST = Aspartate aminotransferase; ALT = alanine aminotransferase.

Table 4. Dose-limiting toxicity (n = 27)

Study cohort	Patients	Patients with DLT	DLT	Total dose at DLT, Gy
1 (45.6 Gy)	6 ^a	1	suspension of treatment for >10 days ^b	31.2
2 (50.4 Gy)	3	0		
3 (55.2 Gy)	6	2	suspension of treatment for >10 days ^b grade 3 diarrhea	36.0 55.2
4 (60.0 Gy)	6	2	suspension of treatment for >10 days ^b grade 3 ALT elevation	31.2 46.8
5 (64.8 Gy)	6	1	grade 4 thrombocytopenia	52.8

ALT = Alanine aminotransferase.

^a One patient developed gastric ulcer 3 months after the completion of chemoradiotherapy.

^b Due to nausea/vomiting and anorexia.




Fig. 1. Overall survival curve and progression-free curve of 29 patients who received hyperfractionated radiotherapy with protracted 5-FU infusion for locally advanced pancreatic cancer. Vertical lines indicate censored cases.

Table 5. Patterns of initial disease progression

Progression	Patients	
	n	%
None	10	34
Local	2	7
Distant	15	52
Liver	8	
Lymph nodes	3	
Peritoneum	1	
Liver and peritoneum	2	
Lung and peritoneum	1	
Local and distant ^a	2	7

^a Peritoneum.

50% in 12 (55%) of 22 patients who had a pretreatment level of 100 U/ml or greater. Disease progression and death from cancer were documented in 19 and 13 patients, respectively, at the time of analysis. The initial sites of disease progression are listed in table 5. Distant metastases predominated over local progression. The median progression-free time and 1-year progression-free rate were 5.4 months and 20.2%, respectively. The median survival time (MST) and 1-year survival rate were 12.2 months and 55.0%, respectively (fig. 1).

Discussion

Based on previous randomized trials, concurrent external-beam radiotherapy and chemotherapy have been the treatment of choice for locally advanced, unresectable pancreatic cancer [1, 2]. Nevertheless, there is substantial room for improvement in chemoradiotherapy for pancreatic cancer because chemoradiotherapy has achieved only modest improvements in median survival and minimal increase in long-term survival to date [3]. Therefore, there is a clear need to establish more effective chemoradiotherapy for locally advanced pancreatic cancer.

Since local relapse of disease after chemoradiotherapy remains high, local tumor control and systemic chemotherapy are necessary for locally advanced pancreatic cancer. To intensify local tumor control, numerous clinical trials have been performed with specialized radiotherapy techniques, including intraoperative radiotherapy, brachytherapy, high-dose conformal radiotherapy and hyperfractionated radiation therapy [7–9, 12–15]. It is noteworthy that relatively good local tumor control and survival were achieved in these trials in which a higher dose was given using external-beam radiotherapy combined with either intraoperative radiotherapy or brachytherapy. These findings suggest the efficacy of dose-intensive radiotherapy for locally advanced pancreatic cancer.

Hyperfractionation is expected to produce a differential effect between the response in tumor and normal tissues. The basic rationale of hyperfractionation is that the use of small dose fractions allows higher total doses to be administered within the tolerance of late-responding normal tissues and that this translates to a higher biologically effective dose to the tumor [4]. Other rationales for hyperfractionation are radiosensitization through redistribution and reduced dependence on oxygen effect [4, 16, 17]. Clinical trials have demonstrated that hyperfractionated radiotherapy has a favorable treatment efficacy in some types of tumors, including head and neck cancer and lung cancer [5, 6].

With regard to pancreatic cancer, however, only limited information about hyperfractionated radiation is available. In 1990, the Gastrointestinal Tumor Study Group reported on hyperfractionated radiation therapy in patients with locally advanced pancreatic cancer [7]. In this study, 18 patients received two fractions of 1.2 Gy each per day (total 50.4 Gy) and bolus 5-FU infusion (350 mg/m²) on the first 3 and last 3 days of radiation therapy. However, the study results were not encouraging: the MST and 1-year survival rate were 35 weeks and

Table 6. Comparison of toxicity, response rate and MST

Toxicity and response	Patients, n (%)	
	current study (n = 29)	conventional regimen (n = 20)
≥ Grade 2 toxicity		
Leukocytopenia	8 (28)	4 (20)
Thrombocytopenia	1 (3)	0 (0)
Nausea/vomiting	21 (72)	3 (15)
Diarrhea	2 (7)	0 (0)
Stomatitis	0 (0)	3 (15)
ALT elevation	5 (17)	2 (10)
Response rate	6 (21)	2 (10)

MST was 12.2 months in the current study and 10.4 months in patients treated with the conventional regimen. ALT = Alanine aminotransferase.

39%, respectively. Prott et al. [8] treated 32 patients with locally advanced pancreatic cancer by hyperfractionated radiation therapy (total 44.8 Gy) along with 5-FU and leucovorin (MST, 12.7 months), and Luderhoffs et al. [9] conducted a pilot study using a combination of hyperfractionated radiation (total 45–50 Gy) and continuous infusion of 5-FU in 13 patients (MST, 36 weeks). Summarizing these three trials, although toxicities seemed to be acceptable, improved survival was unfortunately not achieved. However, the total dose of radiation used in these trials might have been insufficient to obtain adequate local tumor control. Therefore, in the current study, we conducted a phase I study, and concluded that the toxicity associated with our regimen was tolerable up to a total dose of 64.8 Gy. Our conclusions were consistent with the results of the recent phase I–II study for locally advanced pancreatic cancer, in which Ashamalla et al. [18] reported that the use of hyperfractionated radiotherapy (2 fractions of 1.1 Gy each per day) to a dose of 63.8 Gy combined with weekly paclitaxel was tolerated. They also reported that good local control was observed following their regimen; complete relief of pain was achieved in 10 of 14 patients, and objective response was achieved in 5 of 17 evaluable patients.

The adverse effects associated with our regimen seemed to be tolerable. There were no life-threatening toxicities, and no treatment-related deaths occurred. However, acute reactions such as gastrointestinal toxicity were more severe compared with conventional regimens

of chemoradiotherapy. Table 6 shows a comparison of adverse effects between our hyperfractionated chemoradiotherapy and the conventional chemoradiotherapy previously performed in our hospital, which consisted of protracted 5-FU infusion (200 mg/m²/day) with current radiation therapy (50.4 Gy in 28 fractions over 5.5 weeks) [19]. Although hematological toxicity did not significantly differ between these two regimens, nausea/vomiting were more frequently observed in the hyperfractionated chemoradiotherapy. As a result, 8 of 29 (28%) patients treated by hyperfractionated chemoradiotherapy required treatment interruption due to gastrointestinal toxicities, and 3 of the 8 patients abandoned chemoradiotherapy. It is interesting that these 3 patients developed such gastrointestinal toxicities before reaching a total radiation dose of 40 Gy (31.2, 36.0, and 31.2 Gy, respectively). Therefore, although this schedule of hyperfractionated radiation therapy was acceptable for most patients with pancreatic cancer, some patients developed severe and/or prolonged acute toxicities at a relatively low total radiation dose. There was no significant association between the gastrointestinal toxicities and pretreatment factors including gender, age, performance status, and tumor location (data not shown).

In the current study, relatively good local tumor control was obtained: 6 patients (21%) achieved a partial response and 19 (66%) remained stable. At the time of analysis, local disease progression had occurred in only 4 (14%) patients. In addition, the MST of 12.2 months was equal or superior to that of previous studies using conventional fractionation [1, 2, 19]. These findings have encouraged us to conduct further trials of hyperfractionated chemoradiotherapy. However, the incidence of distant metastasis did not decrease after treatment in the present study. Therefore, more effective systemic therapy will be necessary to reduce distant metastases and subsequently improve long-term survival.

In conclusion, the toxicity associated with our regimen was tolerable up to dose level 5 (64.8 Gy). Hoping to demonstrate a superior survival benefit for patients with locally advanced pancreatic cancer, we are currently conducting a phase II trial of this hyperfractionated radiation therapy with protracted 5-FU infusion at a dose of 64.8 Gy.

References

- Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. *Cancer* 1981;48:1705-1710.
- Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. *J Natl Cancer Inst* 1988;80:751-755.
- Okada S: Non-surgical treatments of pancreatic cancer. *Int J Clin Oncol* 1999;4:257-266.
- Ang KK, Thames HD, Peters LJ, Perez C: Altered fractionation schedules; in Perez CA, Brady L (eds): *Principles and Practice of Radiation Oncology*. Philadelphia, Lippincott-Raven, 1997, pp 119-142.
- Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M, et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. *Radiother Oncol* 1992;25:231-241.
- Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. *J Clin Oncol* 1990;8:1543-1555.
- Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. *Cancer* 1990;65:1478-1482.
- Prott FJ, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O, Potter R, Sulkowski U, Rube C, Berns T, Willich N: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: Results of a feasibility study. *Br J Cancer* 1997;75:597-601.
- Luderhoffs EC, Gonzalez Gonzalez D, Bakker P: Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. *Radiother Oncol* 1996;40:241-243.
- Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. *J Jpn Soc Cancer Ther* 1993;28:101-130.
- World Health Organization: WHO handbook for Reporting Results of Cancer Treatment. Offset Publication 48. Geneva, World Health Organization, 1979.
- Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. *Cancer* 1988;61:1110-1116.
- Nishimura Y, Hosotani R, Shibamoto Y, Kokubo M, Kanamori S, Sasai K, Hiraoka M, Ohshio G, Imamura M, Takahashi M, Abe M: External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: Analysis of survival rates and complications. *Int J Radiat Oncol Biol Phys* 1997;39:39-49.
- Mohiuddin M, Rosato F, Barbot D, Schuricht A, Biermann W, Cantor R: Long-term results of combined modality treatment with ¹²⁵I implantation for carcinoma of the pancreas. *Int J Radiat Oncol Biol Phys* 1992;23:305-311.
- Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, Phoa SS, Gonzalez Gonzalez D: Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. *Cancer* 2000;89:2222-2229.
- Withers HR: Cell cycle redistribution as a factor in multifraction irradiation. *Radiology* 1975;114:199-202.
- Palcic B, Skarsgard LD: Reduced oxygen enhancement ratio at low doses of ionizing radiation. *Radiat Res* 1984;100:328-339.
- Ashamalla H, Zaki B, Mokhtar B, Colella F, Selim H, Krishnamurthy M, Ross P: Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2003;55:679-687.
- Ishii H, Okada S, Tokuyue K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. *Cancer* 1997;79:1516-1520.

An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer

Hideki Ueno Takuji Okusaka Masafumi Ikeda Yoriko Takezako
Chigusa Morizane

Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

Key Words

Chemotherapy · Pancreatic cancer · Phase II study · S-1 · Pharmacokinetics

Abstract

Objective: The aim of this study was to evaluate the efficacy and toxicity of S-1 in patients with metastatic pancreatic cancer. **Methods:** Patients were required to have a histological diagnosis of pancreatic adenocarcinoma with measurable metastatic lesions, and no prior chemotherapy. S-1 was administered orally at 40 mg/m² twice daily for 28 days with a rest period of 14 days as one course. Administration was repeated until the appearance of disease progression or unacceptable toxicity. A pharmacokinetic study was done on day 1 in the initial 8 patients. **Results:** Nineteen patients were entered into this study. Four patients (21.1%) achieved a partial response with a 95% confidence interval of 6.1–45.6%. No change was noted in 10 patients (52.6%), and progressive disease in 5 patients (26.3%). The median survival time was 5.6 months with a one-year survival rate of 15.8%. The major adverse events were gastrointestinal toxicities such as nausea and anorexia, though most of them were tolerable and reversible. There were no large differences in the pharmacokinetic parameters of S-1 in

patients with pancreatic cancer and those in patients with other cancers. **Conclusion:** S-1 is active and tolerated in patients with metastatic pancreatic cancer, which will be confirmed in the following large-scale phase II study.

Copyright © 2005 S. Karger AG, Basel

Introduction

Pancreatic cancer is among the most lethal of all solid tumors. More than 80% of patients have unresectable disease at diagnosis, and even if resection is performed, the recurrence rate is extremely high. Consequently, only ≤ 5% of all patients with pancreatic cancer survive 5 years after diagnosis [1]. Although pancreatic cancer has been considered as a chemotherapy-resistant tumor, recent studies have demonstrated that gemcitabine is an effective tool for the palliation of symptoms and prolonging survival in patients with advanced pancreatic cancer. However, single-agent gemcitabine has provided limited benefit, with objective response rates of less than 15% and a median survival of less than 6 months [2–8]. Therefore, to improve the prognosis of patients with pancreatic cancer, there is a clear need to identify a new effective chemotherapeutic regimen.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2005 S. Karger AG, Basel
0030-2414/05/0683-0171\$22.00/0

Accessible online at:
www.karger.com/ocl

Hideki Ueno, MD
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
5-1-1 Tsukiji, Chuo-ku
Tokyo 104-0045 (Japan)
Tel. +81 3 3542 2511, Fax +81 3 3542 3815, E-Mail hueno@ncc.go.jp

S-1 is an oral anticancer drug, which consists of tegafur (FT) as a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydropyridine (CDHP) and potassium oxonate (Oxo) [9]. The drug has been developed to improve the tumor-selective toxicity of 5-FU by two biochemical modulators, CDHP and Oxo. CDHP is a competitive inhibitor of dihydropyrimidine dehydrogenase involved in the degradation of 5-FU, and maintains efficacious 5-FU concentrations in plasma and tumor tissues [10]. Oxo, a competitive inhibitor of orotate phosphoribosyltransferase, inhibits phosphorylation of 5-FU in the gastrointestinal tract, and reduces the serious gastrointestinal toxicity associated with 5-FU [11]. S-1 has already demonstrated a potent antitumor effect in clinical studies on various solid tumors [12–18]. The response rates in the late phase II studies for advanced colorectal cancer, non-small cell lung cancer, and head and neck cancer were 35, 22, and 29%, respectively [12–14]. In particular, an excellent antitumor effect was demonstrated in the two late phase II studies for advanced gastric cancer, which resulted in response rates of 49 and 44%, respectively [15, 16]. In these late phase II studies, S-1 was administered at a dose of 80 mg/m²/day for 28 consecutive days followed by a rest period of 14 days, based on the experience of the early phase II studies [17, 18]. The major adverse events recognized in these studies were myelosuppression and gastrointestinal toxicities, though most of them were tolerable and reversible. According to these findings, the commercial availability of S-1 for the treatment of patients with gastric cancer, colorectal cancer and head and neck cancer has been approved in Japan.

As for pancreatic cancer, although the preclinical antitumor efficacy of S-1 on human pancreatic cancer xenografts implanted into nude rats has been reported [19], its clinical activity against pancreatic cancer has not been evaluated. As it is available in an oral form, S-1 has a potential advantage as far as the convenience of the patients is concerned, especially in terms of quality of life. This is very important in pancreatic cancer patients, because the remaining life span of these patients is generally short. Thus, we conducted an early phase II study to evaluate the antitumor effect and safety of S-1 in patients with metastatic pancreatic cancer.

Patients and Methods

Study Patients

All patients were required to show histologically proven pancreatic adenocarcinoma with measurable metastatic lesions. Additional criteria included the following: no history of prior antitumor treat-

ment except pancreatic resection; 20–74 years of age; Karnofsky performance status of 80–100 points; estimated life expectancy ≥ 2 months; adequate marrow function (white blood cell count 4,000–12,000/mm³, platelet count $\geq 100,000$ /mm³, hemoglobin level ≥ 10.0 g/dl), adequate renal function (normal serum creatinine level), adequate liver function (total bilirubin level ≤ 3 times upper normal limit, transaminases levels ≤ 2.5 times upper normal limit), and written informed consent from the patients. Patients were excluded if there was a history of drug hypersensitivity, serious complications, symptoms attributable to brain metastasis, active secondary cancer, active infection, marked pleural or peritoneal effusion, and watery diarrhea. Pregnant or lactating women were also excluded. The study was performed in accordance with the Declaration of Helsinki, approved by the institutional review board at the National Cancer Center Hospital, and conducted in accordance with the Good Clinical Practice guidelines in Japan.

Treatment Schedule

S-1 was administered orally at 40 mg/m² twice daily after breakfast and dinner. Three initial doses were established according to the body surface area (BSA) as follows: BSA < 1.25 m², 80 mg/day; 1.25 m² \leq BSA < 1.50 m², 100 mg/day; and 1.50 m² \leq BSA, 120 mg/day. S-1 was administered at the respective dose for 28 days, followed by a 14-day rest period. This schedule was repeated every 6 weeks until the occurrence of disease progression, unacceptable toxicities, or the patient's refusal to continue. If grade 3 or higher hematological toxicity or grade 2 or higher nonhematological toxicity was observed, the temporary interruption of S-1 and/or the dose reduction by 20 mg/day was allowed (minimum dose, 80 mg/day). Unless adverse events appeared, to enhance the pharmacological effect, the rest period was shortened to 7 days or the dose was gradually escalated in the next course (maximum dose, 150 mg/day), or both were permitted according to the judgment of individual physicians. If a rest period of more than 28 days was required, the patient was withdrawn from the study. During the treatment, patients maintained a daily journal to record their S-1 intake and any adverse events experienced. S-1 was provided by Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan).

Evaluation of Response and Safety

The response was assessed using computed tomography scan or magnetic resonance imaging in each course according to the Japan Society for Cancer Therapy Criteria [20], which is basically similar to the World Health Organization Criteria. Briefly, complete response was defined as the complete disappearance of all measurable and assessable lesions for at least 4 weeks. Partial response was defined as a $\geq 50\%$ reduction in the sum of the products of the greatest perpendicular diameters of all measurable lesions for at least 4 weeks. No change was defined as a $< 50\%$ reduction or a $< 25\%$ increase in the products of the greatest perpendicular diameters of all lesions for at least 4 weeks. Progressive disease (PD) was defined as a $\geq 25\%$ increase or the appearance of new lesions. Primary pancreatic lesions were considered to be assessable but not measurable lesions, because it is difficult to measure the size of primary pancreatic lesions accurately [21].

Physical examination, complete blood cell counts, biochemistry tests, and urinalysis were assessed weekly during the treatment. Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria version 2.0. An external review committee confirmed the objective responses and adverse events.

Table 1. Patient characteristics (n = 19)

Characteristics	Patients	%
Gender		
Male	13	68
Female	6	32
Median age, years (range)	61 (45–73)	
Karnofsky performance status		
100 points	2	11
90 points	16	84
80 points	1	5
Median first dose, mg/m ² (range)	36.7 (33.7–39.9)	
History of pancreatectomy	1	5
Sites of metastasis		
Liver	15	79
Distant lymph node	3	16
Lung	3	16
Peritoneum	1	5
Median CEA, ng/ml (range)	8.6 (0.4–121)	
Median CA 19-9, U/ml (range)	4,033 (1–155,400)	

Pharmacokinetics

A pharmacokinetic study was performed in the first 8 patients enrolled in the study. Blood (5 ml) was collected with a heparinized syringe on day 1 of the first course before and 1, 2, 4, 6, 8, 10, and 12 h after the administration of S-1. Plasma was separated by centrifugation, and stored at –20°C until analysis. Plasma concentrations of FT, 5-FU, CDHP, and Oxo were quantified as reported previously [22]. FT was quantified by high-performance liquid chromatography with UV detection, and 5-FU, CDHP, and Oxo were quantified by gas chromatography-negative ion chemical ionization mass spectrometry.

Pharmacokinetic parameters, maximum plasma concentration (C_{\max} , ng/ml), time to reach C_{\max} (T_{\max} , h), area under the concentration versus time curve zero to infinity ($AUC_{0-\infty}$, ng·h/ml), and elimination half-life ($T_{1/2}$, h) were calculated by a noncompartment model in Win-Nonlin Version 3.1 (Pharsight, Apex, NC, USA).

Statistical Analysis

The response duration was calculated from the day of the first demonstration of response until PD; time to progression was calculated from the date of study entry until documented PD; overall survival time was calculated from the date of study entry to the date of death or the date of the last follow-up. Median probability of survival and the median time to progression were estimated by the Kaplan-Meier method. Compliance was calculated for all the courses using the ratio of the total dose actually administered to the scheduled dose. Analysis was planned to be carried out when 19 patients were enrolled. In this study, the threshold rate was defined as 5% and the expected rate was set as 15%. If the lower limit of the 90% confidence interval exceeded the 5% threshold (objective response in 4 or more of the 19 patients), S-1 was judged to be effective and we would proceed to the next large-scale study. If the upper limit of the 90% confidence interval did not exceed the expected rate of 15% (no objective response in the 19 patients), S-1 was judged to be ineffective and the study was to be ended. If response was confirmed in 1–3 of the 19 patients, whether to proceed to the next study or not was judged based on the safety and survival data from the present study.

Results

Patients

Nineteen consecutive patients with metastatic pancreatic cancer were enrolled in this study between June 2000 and January 2001 at the National Cancer Center Hospital. All patients were eligible and assessable for responses and adverse events. The patient characteristics are shown in table 1. The Karnofsky performance status was 80–100 points in all patients, and 18 of the 19 showed a Karnofsky performance status of ≥ 90 . Before chemotherapy, morphine was prescribed for 7 patients due to abdominal and/or back pain.

Treatments

A total of 56 courses were administered to the 19 patients with a median of 2 courses per patient (range, 1–12). The initial administered dose of S-1 was 100 mg/day in 8 patients and 120 mg/day in 11 patients. Dose reduction was required in one patient because of grade 3 nausea, vomiting, and anorexia. The compliance rate of the patients taking S-1 during all the courses was as good as 90%.


Response and Survival

Out of the total of 19 evaluable patients, although no complete response was seen, partial response was obtained in 4 patients, resulting in an overall response rate of 21.1% (95% CI, 6.1–45.6%). No change was noted in 10 patients (52.6%), and PD in 5 patients (26.3%).

Table 2. Characteristics of responding patients (n = 4)

Patient No.	Gender	Age	KPS	History of pancrea-tectomy	Sites of metastasis	Symptomatic benefits	Response duration days	Survival time days
7	Female	65	90	No	Liver	Not assessable	78	463+
17	Female	61	90	No	Liver	No change	205	253
18	Female	68	90	No	Lung	No change	418	452+
19	Male	63	90	Yes	Abdominal lymph node	Improved ^a	213	448+

^a Morphine consumption was decreased to $\geq 50\%$ from baseline for 27 weeks without any deterioration of the KPS.

**Fig. 1.** Time to progression (a), and overall survival time (b).

Responses for each of the target sites were 20.0% (3/15) in liver, 33.3% (1/3) in the distant lymph nodes, and 33.3% (1/3) in lung metastases, respectively. The median time from the date of study entry to the day of the first demonstration of response was 34.5 days (range, 31–35 days) and the median response duration was 7.0 months (range, 2.6–13.9 months). The characteristics of all responders are shown in table 2. The median time to progression was 2.6 months, and the overall median survival was 5.6 months with a one-year survival rate of 15.8% (fig. 1). The serum CA 19-9 level was reduced to less than half in 7 (43.8%) of 16 patients who had a pretreatment level of 100 U/ml or greater.

Safety

S-1 was tolerated in this study. Treatment-related adverse events are listed in table 3. The most common adverse events were nausea (grade ≥ 1 , 68.4%) and anorexia (grade ≥ 1 , 57.9%), though most of them were tol-

erable and reversible. Vomiting, stomatitis, diarrhea, and skin rash were generally mild and less frequent, and no serious hepatic or renal toxicities were observed. As to hematological toxicities, grade ≥ 3 neutropenia was noted in only one patient (5.3%), and no grade ≥ 3 thrombocytopenia was observed. Although most patients could be treated as an outpatient without severe adverse events, 3 patients required hospitalization due to grade 3 ileus. Ileus occurred in the first course of treatment in 2 patients, and the remaining one had this event in the sixth course of treatment. However, all of them recovered from ileus after interruption of the S-1 with appropriate treatment. No other severe or unexpected adverse events were noted. Although 2 patients died within 2 months due to rapid disease progression, no treatment-related deaths were observed.

Table 3. Treatment-related adverse events (n = 19): worst grade reported during treatment period

Toxicity	Grade				Grade 1–4	Grade 3–4
	1	2	3	4	%	%
Hematological						
Leukopenia	1	1	0	0	10.5	0
Neutropenia	1	1	1	0	15.8	5.3
Hemoglobin	1	5	1	0	36.8	5.3
Thrombocytopenia	6	0	0	0	31.6	0
Nonhematological						
Nausea	10	0	3	0	68.4	15.8
Vomiting	4	1	1	0	31.6	5.3
Anorexia	6	2	2	1	57.9	15.8
Stomatitis	5	0	0	0	26.3	0
Diarrhea	2	1	1	0	21.1	5.3
Abdominal distension	3	0	2	0	26.3	10.5
Ileus	0	0	3	0	15.8	15.8
Colitis	0	0	2	0	10.5	10.5
Fatigue	3	1	1	0	26.3	5.3
Skin rash	2	1	0	0	15.8	0
Pigmentation	2	2	0	0	21.1	0
Aspartate aminotransferase	3	0	0	0	15.8	0
Alanine aminotransferase	1	2	0	0	15.8	0
Creatinine	0	0	0	0	0	0

Table 4. Pharmacokinetic parameters of FT, 5-FU, CDHP, and Oxo after administration of S-1 (n = 8)

	C_{\max} ng/ml	T_{\max} h	$AUC_{0-\infty}$ ng·h/ml	$T_{1/2}$ h
FT	1,705 ± 383	2.9 ± 1.2	23,846 ± 9,848	8.9 ± 2.4
5-FU	125.7 ± 46.8	4.0 ± 1.1	680.5 ± 252.1	1.9 ± 0.3
CDHP	217.3 ± 100.6	3.0 ± 1.1	1,139.3 ± 335.7	2.9 ± 0.4
Oxo	48.7 ± 51.1	2.4 ± 1.1	253.3 ± 277.6	2.4 ± 0.8

Parameters are represented as mean ± SD.




Fig. 2. Plasma concentration-time profiles of FT (●), 5-FU (○), CDHP (■), and Oxo (□) after administration of S-1 (n = 8). The values are expressed as the mean ± SD.

Pharmacokinetics

The pharmacokinetic parameters (C_{\max} , T_{\max} , $AUC_{0-\infty}$, and $T_{1/2}$) for FT, 5-FU, CDHP, and Oxo are listed in table 4. Plasma concentrations of all compounds peaked between 2 and 4 h after administration. The plasma con-

centration of FT reached a plateau after C_{\max} , which was maintained for 12 h, while 5-FU, CDHP, and Oxo were more rapidly eliminated from the systemic circulation (fig. 2).